Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R

Open source

DOI: 10.3390/ijms18020415
Published: 2017 Feb 15
Container: International journal of molecular sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/ijms18020415,
  title = {Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.},
  author = {Pleyer L and Döhner H and Dombret H and Seymour JF and Schuh AC and Beach CL and Swern AS and Burgstaller S and Stauder R and Girschikofsky M and Sill H and Schlick K and Thaler J and Halter B and Machherndl Spandl S and Zebisch A and Pichler A and Pfeilstöcker M and Autzinger EM and Lang A and Geissler K and Voskova D and Sperr WR and Hojas S and Rogulj IM and Andel J and Greil R},
  year = {2017},
  journal = {International journal of molecular sciences},
  doi = {10.3390/ijms18020415},
  url = {https://doi.org/10.3390/ijms18020415}
}

RIS

TY  - JOUR
TI  - Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
AU  - Pleyer L
AU  - Döhner H
AU  - Dombret H
AU  - Seymour JF
AU  - Schuh AC
AU  - Beach CL
AU  - Swern AS
AU  - Burgstaller S
AU  - Stauder R
AU  - Girschikofsky M
AU  - Sill H
AU  - Schlick K
AU  - Thaler J
AU  - Halter B
AU  - Machherndl Spandl S
AU  - Zebisch A
AU  - Pichler A
AU  - Pfeilstöcker M
AU  - Autzinger EM
AU  - Lang A
AU  - Geissler K
AU  - Voskova D
AU  - Sperr WR
AU  - Hojas S
AU  - Rogulj IM
AU  - Andel J
AU  - Greil R
PY  - 2017
JO  - International journal of molecular sciences
DO  - 10.3390/ijms18020415
UR  - https://doi.org/10.3390/ijms18020415
ER  -

APA

L, P., H, D., H, D., JF, S., AC, S., CL, B., AS, S., S, B., R, S., M, G., H, S., K, S., J, T., B, H., S, M. S., A, Z., A, P., M, P., EM, A., A, L., K, G., D, V., WR, S., S, H., IM, R., J, A., & R, G. (2017). Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.. International journal of molecular sciences. https://doi.org/10.3390/ijms18020415

Source records

pubmed · retrieved 2026-11-11T02:01:02.553Z